Project Partners

Please click on partner logos for links.

The Queen’s University of Belfast

Prof. Sandra Van Schaeybroek is Coordinator of the MErCuRIC project, responsible for overseeing the translational and clinical aspects of the project. The research groups of Prof. Van Schaeybroek, Prof. Mark Lawler and Prof. Patrick Johnston in the Centre for Cancer Research and Cell Biology (CCRCB) at Queen’s University Belfast have extensive experience in translational approaches to cancer therapy that will inform the work of the project. Queen’s is pioneering new approaches to cancer therapy at the CCRCB and has a long term commitment to personalized medicine.

Vall d´Hebron Institute of Oncology

Led by Prof. Josep Taberno, VHIO will recruit patients to the MErCuRIC Phase I trial and lead and recruit patients to the Phase II trial, leveraging their extensive international experience running clinical trials. VHIO has been a leader in the shift to molecular medicine in recent decades.

The Chancellor, Masters and Scholars of The University Of Oxford

Prof. Mark Middleton and Prof. Tim Maughan in the Department of Oncology will lead the Oxford work in MErCuRIC. Prof. Maughan leads one of the UK’s leading research groups in gastrointestinal cancers, while Prof. Middleton brings a wealth of expertise in clinical research into modulating resistance to anticancer agents.

With Prof. Middleton acting as Chief Investigator, Oxford will sponsor and manage the international MErCuRIC clinical trials through the Oncology Clinical Trials Office. The group already has experience in leading UK based clinical trials in metastatic colorectal cancer. Dr. Sharon Love of the Centre for Statistics in Medicine will be responsible for trial statistics. Oxford will recruit patients to both Phase I and II trials.

Universitair Ziekenhuis Antwerpen

Led by Prof. Dr. Marc Peeters, the team at the Multidisciplinary Oncological Centre of Antwerp (MOCA) at the University Hospital of Antwerp has a long standing interest in colorectal cancer and bring substantial clinical trial experience. Prof. Peeters and his group are interested in drug resistance mechanisms and novel therapeutic approaches. UZA will recruit patients to the Phase I and II trials in MErCuRIC.

Velindre National Health Service Trust

The Velindre Cancer Centre within the Velindre National Health Service Trust will participate in MErCuRIC. The Clinical Trials Unit in VCC will oversee recruitment to the MErCuRIC trials with Dr. Robert Jones leading the Phase I trial and Dr. Richard Adams leading the Phase II trial.

Royal College of Surgeons In Ireland

As a pioneer of systems medicine, RCSI has had a long term focus on translating basic research into clinical practice. The College is involved in several European projects targeting colorectal cancer. The MErCuRIC initiative in RCSI is led by Prof. Brian Hennessy. RCSI will recruit patients to the Phase I and II trials, as well as providing translational research expertise in Sequenom technologies to develop a high throughput analysis platform based on predictive genetic profiles.

Universite Paris Descartes

Within the Faculty of Medicine at the Paris Descartes University Medical School, Prof. Laurent-Puig is developing several new markers for colorectal cancer and methods for drug response prediction. The PDUM team brings world leading experience in targets relevant to colorectal cancer to the MErCuRIC project. During the project, PDUM will contribute to translational aspects of the research programme (qPCR, Next Generation Sequencing).

Universita Degli Studi di Torino

The team of Prof. Alberto Bardelli in the Department of Oncology at UNITO are pioneers in the tailoring of drug combinations to overcome resistance. During MErCuRIC, the group will contribute to translational research aspects of the project, providing expertise in identifying resistance biomarkers, ctDNA based biopsies and xenopatient based drug testing.

Assistance Publique – Hopitaux de Paris

The Department of Medical Oncology at Saint-Antoine Hospital and the Department of Digestive Oncology at Georges-Pompidou Hospital are both world leading centres in gastrointestinal research. Led by Prof. Thierry André, APHP will recruit patients to the MErCuRIC Phase I and II trials on both sites, with Dr. Geraldine Perkins as principal investigator for Georges-Pompidou Hospital.

Multiplicom Nv

MTP develops innovative Next Generation Sequencing technologies. They focus on delivering molecular diagnostics for congenital diseases. Led by Prof. Jurgen Del-Favero, the MTP team will develop a state-of-the-art diagnostic test to detect specific cancer mutations during the MErCuRIC project, based on their Multiplex PCR technology.

Masarykova Univerzita

The team of Dr. Vladimir Popovici at the Institute of Biostatistics and Analyses, Masarykova Univerzita will provide a suite of omics platforms to interrogate clinical data from the MErCuRIC trials. The team have a track record in the development of biomarkers in breast and colorectal cancer, with substantial bioinformatics experience that will be leveraged to analyze the aggregated data from the project.

Pintail

Led by Director Ciaran Clissmann, Pintail bring substantial experience in the administration of international European research projects, as well as dissemination and communications. Pintail are involved in a number of related cancer projects (APO-DECIDE, Angio-Predict), working with many of the same partners as in MErCuRIC.

Belfast Health and Social Care Trust

BHSCT is a national specialist services provider in Northern Ireland, with a commitment to delivering integrated health and social care. Through the Northern Ireland Cancer Research Consumer Forum (NICRCF), BHSCT will contribute the perspective of patients to the MErCuRIC project. In addition, the team of Dr. Richard Wilson at the Northern Ireland Cancer Trials Centre will bring substantial clinical trial experience to the project, and oversee recruitment of patients to the Phase I and II trial. BHSCT will also contribute to Next Generation Sequencing through the expertise of Prof. Manuel Salto-Tellez.